Revvity, Inc. RVTY
167.22 USD +15.62 (+10.30%)
Nov 3, 2026, 3:24 PM EST
162.58 Day range 171.74
81.22 52-week range 171.74
- YTD
- +72.83%
- 1 year
- +79.86%
News
seekingalpha.com Revvity, Inc. (RVTY) Q3 2026 Earnings Call Transcript Revvity, Inc. (RVTY) Q3 2026 Earnings Call Transcript
zacks.com RVTY Q3 Earnings Beat Estimates on Life Sciences Strength, '26 View Up Revvity's Q3 2026 earnings and revenues beat estimates, fueled by Life Sciences growth and margin expansion, prompting an upward revision to its annual outlook.
benzinga.com Revvity Stock Hits 52-Week High - Here's Why Revvity (RVTY) hits a new 52-week high after topping Q3 earnings estimates and raising its full-year guidance on strong biotech and AI demand.
benzinga.com Fabrinet, EverQuote, Lattice Semiconductor, Fiserv And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed as Dow fell 200 points; Fabrinet surged 13.7% on strong results, guidance and buyback, while several small caps rallied.
investors.com Revvity Faced Off With 'Elevated Investor Expectations' — And Won Medical research stock Revvity surged on the back of a strong third-quarter report and heightened 2026 view.
benzinga.com Revvity Q3 2026 Earnings Call Transcript Revvity (NYSE:RVTY) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
zacks.com Revvity (RVTY) Tops Q3 Earnings and Revenue Estimates Revvity (RVTY) came out with quarterly earnings of $1.38 per share, beating the Zacks Consensus Estimate of $1.29 per share. This compares to earnings of $1.18 per share a year ago.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Dyadic International (NASDAQ:DYAI) stock rose 13.4% to $0.43 during Tuesday's pre-market session. The market value of their outstanding shares is at $15.0 million. Aethlon Medical…
benzinga.com CORRECTION: Revvity Raises FY2026 Adj EPS Guidance from $5.30-$5.40 to $5.40-$5.45 vs $5.35 Est; Raises FY2026 Sales Guidance from $2.830B-$2.860B to $2.860B vs $2.865B Est Revvity (NYSE:RVTY) raises FY2026 Adj EPS guidance from $5.30-$5.40 to $5.40-$5.45 vs $5.35 analyst estimate. Raises FY2026 sales outlook from $2.830 billion-$2.860 billion to $2.860 billion vs…
benzinga.com Revvity Q3 Adj. EPS $1.38 Beats $1.30 Estimate, Sales $728.899M Beat $698.155M Estimate Revvity (NYSE:RVTY) reported quarterly earnings of $1.38 per share which beat the analyst consensus estimate of $1.30 by 6.15 percent. This is a 16.95 percent increase over earnings of $1.18 per…
businesswire.com Revvity Announces Financial Results for the Third Quarter of 2026 WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended October 4, 2026. The Company reported GAAP earnings per share from continuing…
businesswire.com Revvity Board Declares Quarterly Dividend WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on…
zacks.com Revvity Gears Up to Post Q3 Earnings: What's in Store for the Stock? RVTY's Q3 earnings may gain from recovering pharma demand, stronger HCS demand and software growth, despite lingering spending and TB-related headwinds.
zacks.com GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
seekingalpha.com Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And Detractors The Fund declined 4.75% while the Russell 2500 Index declined 6.37%. Key contributors include Illumina, Revvity and Waystar. Key detractors include Regal Rexnord, Knife River and Red Rock Resorts.
zacks.com Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report? Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zacks.com Revvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com ELV vs. RVTY: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV) or Revvity (RVTY). But which of these two stocks offers value investors a better bang…
zacks.com Revvity Launches Signals LabGistics to Coordinate Scientific Workflows RVTY's AI-first Signals LabGistics aims to streamline scientific workflows, enhance R&D-to-manufacturing coordination and expand software growth opportunities.
seekingalpha.com Revvity: A Diagnostics Annuity Is Quietly Funding An AI Data Engine Revvity is transforming from a legacy tools company into a diagnostics-driven, AI-enabled platform with robust double-digit diagnostics growth. The Diagnostics segment organic revenue rose 11%, while…
businesswire.com Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced that its Revvity Signals Software business is launching the Signals LabGistics™ solution, an AI-first, scientific workflow…
etftrends.com How to Invest in AI Drug Discovery .Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to…
benzinga.com Here's How Much $100 Invested In Revvity 15 Years Ago Would Be Worth Today Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.91% on an annualized basis producing an average annual return of 15.11%. Currently, Revvity has a market capitalization of…
benzinga.com TD Cowen Maintains Buy on Revvity, Raises Price Target to $175 TD Cowen analyst Dan Brennan maintains Revvity (NYSE:RVTY) with a Buy and raises the price target from $130 to $175.
businesswire.com Revvity to Present at Upcoming Investor Conferences WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: 2026 Jefferies Global Healthcare Conference Tuesday, November 17,…
benzinga.com Barclays Maintains Equal-Weight on Revvity, Raises Price Target to $160 Barclays analyst Luke Sergott maintains Revvity (NYSE:RVTY) with a Equal-Weight and raises the price target from $115 to $160.
benzinga.com Revvity Nears 52-Week High, but This Analyst Thinks Stock Can Climb Another 20% William Blair initiates Revvity (RVTY) at Outperform, citing AI tailwinds, life sciences recovery, and potential 20%+ stock upside.
businesswire.com Revvity to Host Investor Day WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET.Presentations from members of Revvity's senior…
zacks.com Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock? Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
businesswire.com Revvity to Hold Earnings Call on November 3, 2026 WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The…
defenseworld.net Revvity (NYSE:RVTY) Hits New 12-Month High – Here’s Why Revvity Inc. (NYSE: RVTY - Get Free Report) shares reached a new 52-week high on Thursday. The stock traded as high as $158.28 and last traded at $153.6540, with a volume of 4432400 shares trading…
zacks.com Here's Why You Should Retain Revvity Stock in Your Portfolio for Now RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.
benzinga.com Full Transcript: Revvity Q2 2026 Earnings Call Revvity (NYSE:RVTY) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga…
benzinga.com Here’s How Much You Would Have Made Owning Revvity Stock In The Last 15 Years Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.11% on an annualized basis producing an average annual return of 14.72%. Currently, Revvity has a market capitalization of…
benzinga.com Revvity Rolls Out GSP T1D 3plex Kit Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide…
benzinga.com Fed Raises Rates, Yields Hit 2007 Highs as Fuel Costs Set Records: This Week On Wall Street The Fed hiked for the first time since 2023; the 10-year yield touched 5.04%, and record diesel prices hit truckers and automakers.- benzinga.com Here’s How Much You Would Have Made Owning Revvity Stock In The Last 15 Years Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.11% on an annualized basis producing an average annual return of 14.61%. Currently, Revvity has a market capitalization of…
benzinga.com 10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
benzinga.com Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition Revvity buys Human Cell Design to expand diabetes and GLP-1 drug discovery tech. Acquisition expected to close in Q4 2026.- benzinga.com Revvity To Acquire French Biotech Firm Human Cell Design To Gain Exposure To Human Cell Models And Preclinical Research Solutions For Diabetes, Obesity And Other Metabolic Diseases The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications…
- benzinga.com Keybanc Maintains Overweight on Revvity, Raises Price Target to $165 Keybanc analyst Paul Knight maintains Revvity (NYSE:RVTY) with a Overweight and raises the price target from $125 to $165.
- benzinga.com RBC Capital Initiates Coverage On Revvity with Sector Perform Rating, Announces Price Target of $135 RBC Capital analyst Dan Leonard initiates coverage on Revvity (NYSE:RVTY) with a Sector Perform rating and announces Price Target of $135.
- benzinga.com Evercore ISI Group Maintains Outperform on Revvity, Raises Price Target to $126 Evercore ISI Group analyst Vijay Kumar maintains Revvity (NYSE:RVTY) with a Outperform and raises the price target from $125 to $126.
benzinga.com Transcript: Revvity Q2 2026 Earnings Conference Call Revvity (NYSE:RVTY) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts…
benzinga.com Revvity Raises FY2026 Adj EPS Guidance from $5.20-$5.30 to $5.30-$5.40 vs $5.27 Est; Raises FY2026 Sales Guidance from $2.810B-$2.840B to $2.830B-$2.860B vs $2.858B Est Revvity (NYSE:RVTY) raises FY2026 Adj EPS guidance from $5.20-$5.30 to $5.30-$5.40 vs $5.27 analyst estimate. Raises FY2026 sales outlook from $2.810 billion-$2.840 billion to $2.830 billion-$2.860…
benzinga.com Revvity Q2 Adj. EPS $1.41 Beats $1.22 Estimate, Sales $729.688M Beat $709.035M Estimate Revvity (NYSE:RVTY) reported quarterly earnings of $1.41 per share which beat the analyst consensus estimate of $1.22 by 15.57 percent. This is a 19.49 percent increase over earnings of $1.18 per…
benzinga.com Evercore ISI Group Maintains Outperform on Revvity, Raises Price Target to $125 Evercore ISI Group analyst Vijay Kumar maintains Revvity (NYSE:RVTY) with a Outperform and raises the price target from $110 to $125.
benzinga.com Bernstein Reinstates Market Perform on Revvity, Announces $115 Price Target Bernstein analyst Eve Burstein reinstates Revvity (NYSE:RVTY) with a Market Perform and announces $115 price target.- benzinga.com Revvity Launches Signals AI Scientists can now search, understand and act on complex R&D data in natural language by leveraging leading LLM capabilities within the Signals One platformGoverned data and ontology-driven…
- benzinga.com Barclays Maintains Equal-Weight on Revvity, Raises Price Target to $105 Barclays analyst Luke Sergott maintains Revvity (NYSE:RVTY) with a Equal-Weight and raises the price target from $95 to $105.